menu
    • menu
    [{"orgOrder":0,"company":"Alfasigma","sponsor":"PhaseBio Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"Bentracimab","moa":"P2Y12 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Alfasigma","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0.25,"dosageForm":"Intravenous Infusion","sponsorNew":"Alfasigma \/ Alfasigma","highestDevelopmentStatusID":"10","companyTruncated":"Alfasigma \/ Alfasigma"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Intercept Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Obeticholic Acid","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Alfasigma","amount2":0.79000000000000004,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","amount2New":0.79000000000000004,"dosageForm":"Tablet","sponsorNew":"Alfasigma \/ Alfasigma","highestDevelopmentStatusID":"12","companyTruncated":"Alfasigma \/ Alfasigma"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Intercept Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Obeticholic Acid","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Alfasigma","amount2":0.79000000000000004,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","amount2New":0.79000000000000004,"dosageForm":"Tablet","sponsorNew":"Alfasigma \/ Alfasigma","highestDevelopmentStatusID":"12","companyTruncated":"Alfasigma \/ Alfasigma"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Filgotinib","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Alfasigma","amount2":0.23000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0.23000000000000001,"dosageForm":"Tablet, Film Coated","sponsorNew":"Alfasigma \/ Alfasigma","highestDevelopmentStatusID":"12","companyTruncated":"Alfasigma \/ Alfasigma"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Filgotinib","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Alfasigma","amount2":0.17999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0.17999999999999999,"dosageForm":"Tablet, Film Coated","sponsorNew":"Alfasigma \/ Alfasigma","highestDevelopmentStatusID":"12","companyTruncated":"Alfasigma \/ Alfasigma"}]

    Find Clinical Drug Pipeline Developments & Deals by Alfasigma

    Menu

    Alfasigma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alfasigma

                            Italy arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Alfasigma

                            Italy arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Filgotinib

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Recipient : Galapagos

                            Deal Size : $184.9 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Galapagos Completes Transaction to Transfer Jyseleca® Business to Alfasigma

                            Details : Alfasigma completed acquisition of Jyseleca (filgotinib), which provides European and UK Marketing Authorizations. It is used for the treatment of moderate to severe rheumatoid arthritis.

                            Brand Name : Jyseleca

                            Molecule Type : Small molecule

                            Upfront Cash : $54.3 million

                            January 31, 2024

                            Lead Product(s) : Filgotinib

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Recipient : Galapagos

                            Deal Size : $184.9 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alfasigma

                            Italy arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Alfasigma

                            Italy arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Filgotinib

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Recipient : Galapagos

                            Deal Size : $229.7 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Galapagos Signs Agreement to Transfer Jyseleca® Business to Alfasigma

                            Details : Galapagos transfers Jyseleca (filgotinib) to Alfasigma as part of its transformation into a biotech company focused on immunology and oncology, marking a significant milestone for the company.

                            Brand Name : Jyseleca

                            Molecule Type : Small molecule

                            Upfront Cash : $54.7 million

                            January 02, 2024

                            Lead Product(s) : Filgotinib

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Recipient : Galapagos

                            Deal Size : $229.7 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Alfasigma

                            Italy arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Alfasigma

                            Italy arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obeticholic Acid

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Approved

                            Recipient : Intercept Pharmaceuticals

                            Deal Size : $794.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Alfasigma Completes Acquisition of Intercept Pharmaceuticals, Inc.

                            Details : Through the acquisition, Alfasigma adds Ocaliva (obeticholic acid), a farnesoid X receptor agonist approved in the United States for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate respon...

                            Brand Name : Ocaliva

                            Molecule Type : Small molecule

                            Upfront Cash : $794.0 million

                            November 08, 2023

                            Lead Product(s) : Obeticholic Acid

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Approved

                            Recipient : Intercept Pharmaceuticals

                            Deal Size : $794.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Alfasigma

                            Italy arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Alfasigma

                            Italy arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obeticholic Acid,Ursodeoxycholic Acid

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Approved

                            Recipient : Intercept Pharmaceuticals

                            Deal Size : $794.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of...

                            Details : Through the acquisition, Alfasigma adds Ocaliva (obeticholic acid), a farnesoid X receptor agonist approved in the United States for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate respon...

                            Brand Name : Ocaliva

                            Molecule Type : Small molecule

                            Upfront Cash : $794.0 million

                            September 26, 2023

                            Lead Product(s) : Obeticholic Acid,Ursodeoxycholic Acid

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Approved

                            Recipient : Intercept Pharmaceuticals

                            Deal Size : $794.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Alfasigma

                            Italy arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Alfasigma

                            Italy arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bentracimab

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Recipient : PhaseBio Pharmaceuticals

                            Deal Size : $245.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Alfasigma Buys Back its European License for Bentracimab from PhaseBio

                            Details : Bentracimab is a new human monoclonal antibody fragment which in previous clinical studies has shown an immediate and prolonged reversal of the antiplatelet effects of Brilinta® / Brilique® (ticagrelor).

                            Brand Name : PB2452

                            Molecule Type : Large molecule

                            Upfront Cash : $20.0 million

                            June 22, 2021

                            Lead Product(s) : Bentracimab

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Recipient : PhaseBio Pharmaceuticals

                            Deal Size : $245.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth